Annovis Bio, Inc. Stock-Based Compensation
Annovis Bio, Inc. (ANVS) reported Stock-Based Compensation of $1.79 million for the 6-month period ending 2026-06-30, per its 10-Q filed 2026-08-14.
Financial Statements › Cash Flow › Operating Activities
us-gaap:ShareBasedCompensation · last filed 2026-08-14
- Annovis Bio, Inc. share-based payment arrangement, noncash expense for the quarter ending 2026-06-30 was $1.61M, a 223.92% increase year-over-year.
- Annovis Bio, Inc. share-based payment arrangement, noncash expense for the quarter ending 2026-03-31 was $182.82K, a 63.43% decline year-over-year.
- Annovis Bio, Inc. share-based payment arrangement, noncash expense for the quarter ending 2025-12-31 was $356.52K, a 75.95% decline year-over-year.
- Annovis Bio, Inc. share-based payment arrangement, noncash expense for the quarter ending 2025-09-30 was $444.65K, a 13.12% increase year-over-year.
- Annovis Bio, Inc. share-based payment arrangement, noncash expense for fiscal 2025 was $1.80M, a 53.15% decline from fiscal 2024.
- Annovis Bio, Inc. share-based payment arrangement, noncash expense for fiscal 2024 was $3.84M, a 17.10% decline from fiscal 2023.
- Annovis Bio, Inc. share-based payment arrangement, noncash expense for fiscal 2023 was $4.63M, a 49.43% decline from fiscal 2022.
- Annovis Bio, Inc. share-based payment arrangement, noncash expense for fiscal 2022 was $9.15M, a 94.83% increase from fiscal 2021.
| Period end | Share-based Payment Arrangement, Noncash Expense 3 month | Share-based Payment Arrangement, Noncash Expense 6 month | Share-based Payment Arrangement, Noncash Expense 9 month | Share-based Payment Arrangement, Noncash Expense 12 month |
|---|---|---|---|---|
| 2026-06-30 | $1.61M derived: 10-Q 6 month − 10-Q 3 month · filed 2026-08-14 | $1.79M 10-Q · filed 2026-08-14 | $2.15M derived: sum of 3 quarters · filed 2026-08-14 | $2.59M derived: sum of 4 quarters · filed 2026-08-14 |
| 2026-03-31 | $182.82K 10-Q · filed 2026-05-15 | $539.35K derived: sum of 2 quarters · filed 2026-05-15 | $983.99K derived: sum of 3 quarters · filed 2026-05-15 | $1.48M derived: sum of 4 quarters · filed 2026-08-14 |
| 2025-12-31 | $356.52K derived: 10-K 12 month − 10-Q 9 month · filed 2026-03-13 | $801.17K derived: sum of 2 quarters · filed 2026-03-13 | $1.30M derived: sum of 3 quarters · filed 2026-08-14 | $1.80M 10-K · filed 2026-03-13 |
| 2025-09-30 | $444.65K derived: 10-Q 9 month − 10-Q 6 month · filed 2025-11-12 | $941.26K derived: sum of 2 quarters · filed 2026-08-14 | $1.44M 10-Q · filed 2025-11-12 | $2.92M derived: sum of 4 quarters · filed 2026-08-14 |
| 2025-06-30 | $496.62K derived: 10-Q 6 month − 10-Q 3 month · filed 2026-08-14 | $996.50K 10-Q · filed 2026-08-14 | $2.48M derived: sum of 3 quarters · filed 2026-08-14 | $2.87M derived: sum of 4 quarters · filed 2026-08-14 |
| 2025-03-31 | $499.89K 10-Q · filed 2026-05-15 | $1.98M derived: sum of 2 quarters · filed 2026-05-15 | $2.38M derived: sum of 3 quarters · filed 2026-05-15 | $3.97M derived: sum of 4 quarters · filed 2026-05-15 |
| 2024-12-31 | $1.48M derived: 10-K 12 month − 10-Q 9 month · filed 2026-03-13 | $1.88M derived: sum of 2 quarters · filed 2026-03-13 | $3.47M derived: sum of 3 quarters · filed 2026-03-13 | $3.84M 10-K · filed 2026-03-13 |
| 2024-09-30 | $393.08K derived: 10-Q 9 month − 10-Q 6 month · filed 2025-11-12 | $1.99M derived: sum of 2 quarters · filed 2025-11-12 | $2.35M 10-Q · filed 2025-11-12 | $3.24M derived: sum of 4 quarters · filed 2025-11-12 |
| 2024-06-30 | $1.60M derived: 10-Q 6 month − 10-Q 3 month · filed 2025-08-12 | $1.96M 10-Q · filed 2025-08-12 | $2.84M derived: sum of 3 quarters · filed 2025-08-12 | $3.48M derived: sum of 4 quarters · filed 2025-08-12 |
| 2024-03-31 | $364.76K 10-Q · filed 2025-05-13 | $1.25M derived: sum of 2 quarters · filed 2025-05-13 | $1.88M derived: sum of 3 quarters · filed 2025-05-13 | $3.45M derived: sum of 4 quarters · filed 2025-05-13 |
| 2023-12-31 | $882.38K derived: 10-K 12 month − 10-Q 9 month · filed 2025-03-21 | $1.51M derived: sum of 2 quarters · filed 2025-03-21 | $3.09M derived: sum of 3 quarters · filed 2025-03-21 | $4.63M 10-K · filed 2025-03-21 |
| 2023-09-30 | $632.19K derived: 10-Q 9 month − 10-Q 6 month · filed 2024-11-08 | $2.20M derived: sum of 2 quarters · filed 2024-11-08 | $3.75M 10-Q · filed 2024-11-08 | $5.20M derived: sum of 4 quarters · filed 2024-11-08 |
| 2023-06-30 | $1.57M derived: 10-Q 6 month − 10-Q 3 month · filed 2024-08-14 | $3.11M 10-Q · filed 2024-08-14 | $4.57M derived: sum of 3 quarters · filed 2024-08-14 | $6.93M derived: sum of 4 quarters · filed 2024-08-14 |
| 2023-03-31 | $1.54M 10-Q · filed 2024-05-10 | $3.00M derived: sum of 2 quarters · filed 2024-05-10 | $5.36M derived: sum of 3 quarters · filed 2024-05-10 | $7.26M derived: sum of 4 quarters · filed 2024-05-10 |
| 2022-12-31 | $1.46M derived: 10-K 12 month − 10-Q 9 month · filed 2024-03-29 | $3.81M derived: sum of 2 quarters · filed 2024-03-29 | $5.72M derived: sum of 3 quarters · filed 2024-03-29 | $9.15M 10-K · filed 2024-03-29 |
| 2022-09-30 | $2.36M derived: 10-Q 9 month − 10-Q 6 month · filed 2023-11-08 | $4.26M derived: sum of 2 quarters · filed 2023-11-08 | $7.69M 10-Q · filed 2023-11-08 | $11.57M derived: sum of 4 quarters · filed 2023-11-08 |
| 2022-06-30 | $1.90M 10-Q · filed 2022-08-08 | $5.34M 10-Q · filed 2023-08-14 | $9.22M derived: sum of 3 quarters · filed 2023-05-10 | $10.00M derived: sum of 4 quarters · filed 2023-05-10 |
| 2022-03-31 | $3.43M 10-Q · filed 2023-05-10 | $7.31M derived: sum of 2 quarters · filed 2023-05-10 | $8.10M derived: sum of 3 quarters · filed 2023-05-10 | $8.11M derived: sum of 4 quarters · filed 2023-05-10 |
| 2021-12-31 | $3.88M derived: 10-K 12 month − 10-Q 9 month · filed 2023-03-31 | $4.67M derived: sum of 2 quarters · filed 2023-03-31 | $4.67M derived: sum of 3 quarters · filed 2023-03-31 | $4.70M 10-K · filed 2023-03-31 |
| 2021-09-30 | $785.94K derived: 10-Q 9 month − 10-Q 6 month · filed 2022-11-08 | $793.93K derived: sum of 2 quarters · filed 2022-11-08 | $817.91K 10-Q · filed 2022-11-08 | $942.53K derived: sum of 4 quarters · filed 2022-11-08 |
| 2021-06-30 | $7.99K 10-Q · filed 2022-08-08 | $31.97K 10-Q · filed 2022-08-08 | $156.59K derived: sum of 3 quarters · filed 2022-08-08 | $785.61K derived: sum of 4 quarters · filed 2022-08-08 |
| 2021-03-31 | $23.98K 10-Q · filed 2022-05-04 | $148.60K derived: sum of 2 quarters · filed 2022-05-04 | $777.62K derived: sum of 3 quarters · filed 2022-05-04 | $1.89M derived: sum of 4 quarters · filed 2022-05-04 |
| 2020-12-31 | $124.62K derived: 10-K 12 month − 10-Q 9 month · filed 2022-03-02 | $753.64K derived: sum of 2 quarters · filed 2022-03-02 | $1.86M derived: sum of 3 quarters · filed 2022-03-02 | $1.86M 10-K · filed 2022-03-02 |
| 2020-09-30 | $629.02K 10-Q · filed 2020-11-04 | $1.74M derived: sum of 2 quarters · filed 2020-11-04 | $1.74M 10-Q · filed 2021-11-03 | $1.74M derived: sum of 4 quarters · filed 2021-03-03 |
| 2020-06-30 | $1.11M 10-Q · filed 2020-07-29 | $1.11M 10-Q · filed 2021-07-28 | $1.11M derived: sum of 3 quarters · filed 2021-03-03 | $1.11M derived: sum of 4 quarters · filed 2021-03-03 |
| 2020-03-31 | $0.00 10-Q · filed 2020-05-05 | -$376.00 derived: sum of 2 quarters · filed 2021-03-03 | -$376.00 derived: sum of 3 quarters · filed 2021-03-03 | -$376.00 derived: sum of 4 quarters · filed 2021-03-03 |
| 2019-12-31 | -$376.00 derived: 10-K 12 month − 10-Q 9 month · filed 2021-03-03 | -$376.00 derived: sum of 2 quarters · filed 2021-03-03 | -$376.00 derived: sum of 3 quarters · filed 2021-03-03 | $8.48K 10-K · filed 2021-03-03 |
| 2019-09-30 | $0.00 10-Q · filed 2020-11-04 | $0.00 derived: sum of 2 quarters · filed 2020-11-04 | $8.86K 10-Q · filed 2020-11-04 | |
| 2019-06-30 | $0.00 10-Q · filed 2020-07-29 | $8.86K 10-Q · filed 2020-07-29 | ||
| 2019-03-31 | $8.86K 10-Q · filed 2020-05-05 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| HERON THERAPEUTICS, INC. /DE/ (HRTX) | United States | $0.055B | -2.38 |
| Clene Inc. (CLNN) | United States | $0.054B | -1.99 |
| NOMAD POWER SOLUTIONS, INC. (NMAD) | United States | $0.058B | |
| Serina Therapeutics, Inc. (SER) | United States | $0.054B | -2.35 |
| Boundless Bio, Inc. (BOLD) | United States | $0.059B | -0.88 |
| TALPHERA, INC. (TLPH) | United States | $0.060B | |
| CalciMedica, Inc. (CALC) | United States | $0.061B | -1.42 |
| Xilio Therapeutics, Inc. (XLO) | United States | $0.052B | |
| Skye Bioscience, Inc. (SKYE) | United States | $0.061B | -0.48 |
| Rein Therapeutics, Inc. (RNTX) | United States | $0.063B | -1.76 |